According to Clinical Trials Today, Canadian contract research organization (CRO) ASKA Research entered into strategic partnerships with two CROs that will expand ASKA’s service offerings in North America and in Australia.
The first partnership, with Queensland, Australia-based Clinical Network Services (CNS), was made possible by the Economic Research Agreement between British Columbia and Queensland, which went into effect last June. The agreement is designed to build international relations in key sectors, such as biotechnology and life sciences.
According to ASKA, the partnership with CNS is the first business-to-business partnership resulting from the intergovernmental alliance.
ASKA also entered into a partnership with Winnipeg, Canada-based Clinical Development Solutions (CDS), which focuses on cardiovascular and metabolic disease areas. ASKA and CDS will provide services to one another and their clients to reduce the time to market and production costs.
With ASKA's partnerships going global, will we see a ripple effect from other CROs?
Blog Archive
-
▼
2009
(173)
-
►
November
(8)
- Forced Degradation Brochure Now Available
- Call for Bloggers: Attend Partnerships in Clinical...
- Forced Degradation Forum Brochure Available
- Contract Research Remains Strong According to F&S ...
- A new way to find potential clinical trial partici...
- Partnerships In Clinical Trials Expands Its Global...
- Malaria vaccine trail to begin in east Africa
- Florida Senator wants to see clinical trial expens...
-
►
October
(8)
- PPD Makes Significant Inroad into China Biotech wi...
- Studies may be failing to show adverse effects of ...
- Genzyme begins Phase 3 clinical trial
- Amarin Appoints Medpace as CRO for Two Phase 3 Car...
- Top 5 Clinical Trial Partnering in Asia Pacific Qu...
- Kansas Cancer Center to Join Clinical Trials
- New guidance draft document for REMS
- Adaptive Clinical Trials Benefit Smaller Laborator...
-
►
September
(12)
- Indian drug market to grow to $20 bil in 2015
- Concern for Outsourced Drug Clinical Trials
- Partnerships APAC looks at clinical trials in the ...
- New Bill Might Boost Recruitment Rates for Rare Di...
- Are you interested in clinical trials taking place...
- Clinical trials for medical devices
- Where are Clinical Trials Being Conducted in the U...
- Archived Web Seminar: REMS, EU-RMP and FDAAA: Navi...
- Stem cell treatment fails clinical trial
- H1N1 vaccine trials effective
- Reminder: Free Web Seminar Next Week
- Albany hospital sees increase in cancer clinical t...
-
►
August
(16)
- Pfizer and Private Team Access Launch New Patient ...
- The lack of participation in clincial trials
- Official Call For Papers: Oncology Clinical Trial...
- Outsourcing of clinical trials expected to rise by...
- Pfizer to create online networking site for clinic...
- Medicare's Stance on Clinical Trials
- Medicare's Stance on Clinical Trials
- Stem cells for the heart in clinical trial
- Biopharma in India is Surging
- goBalto, Matchmaking for CROs and Drug Developers
- India Expected to Take Larger Share of Outsourcin...
- Clinical Trial Cost & Contract Management Agenda F...
- Web Seminar: REMS, EU-RMP and FDAAA: Navigating th...
- Repros Therapeutics Inc. halts clinical trial
- Outsourcing to grow 10% says WSHP
- USA and Europe team together to monitor clinical t...
-
▼
May
(15)
- As Sponsors increasingly look to CROs to provide e...
- Shifting Clinical Trial Environment
- Centralized patient recruitment
- Making the Business Case for Improving your Compar...
- Recession, stimulus bill open new doors for CROs
- Top Five States for Biotech Innovation
- ASKA Partners with International CROs
- Encorium looking for a buyer
- Phase III Clinical Trials
- Bio-Imiging Technologies and Phoenix Data Systems ...
- A Look at the 18th Annual Partnerships with CROs
- CASE STUDY: How Do Mergers, Acquisitions and Licen...
- Leveraging Relationship Structures to Optimize Spo...
- Outsourcing Clinical Trials in Emerging Regions: I...
- How to Make Change Part of Your Competitive Advant...
-
►
November
(8)














0 comments:
Post a Comment